GigaGen Inc. has announced FDA approval for its IND application. This permits the start of a Phase 1 trial to evaluate GIGA-564's effectiveness in treating diverse solid cancers.

Biotech company UNITY Biotechnology has launched its Phase 2 ASPIRE trial, administering its aging-focused drug UBX1325 (foselutoclax) to the first patients.

Mabwell announced its Phase III trial application for 9MW2821 vs. standard chemo in advanced urothelial carcinoma.

Hemab Therapeutics has reported the initial dosing of a participant in a Stage 2 medical trial assessing the efficacy of HMB-001 in addressing Glanzmann's Thrombasthenia.

NAYA Biosciences Reveals New Findings on Its CD38-Directed Flex-NK™ Dual-Specific Antibody in the Journal Published by the American Society of Hematology.

IASO Bio alongside Innovent unveiled fresh Equecabtagene Autoleucel (FUCASO®) findings for those affected by multiple myeloma, during the 2023 ASH conference.

Qilu Pharma Releases Initial Clinical Data on New Dual-Target Antibody QLS31905 During ESMO Immuno-Oncology Meeting.

Electra Therapeutics unveils initial study results from their active Phase 1b trial of ELA026 designed to combat secondary HLH (hemophagocytic lymphohistiocytosis)

Agenus Inc., an innovator in immune-modulatory cancer treatments, announced reaching its second milestone in the global licensing agreement with Bristol Myers Squibb for BMS-986442, a bispecific TIGIT antibody with improved Fc functionality.

Atara Biotherapeutics Unveils Encouraging Early Research Results for ATA3431, an Innovative Off-the-Shelf CAR Therapy Aimed at CD20 and CD19, at the 65th Annual Session of ASH.

The FDA has approved Pfizer’s review request for marstacimab, a hemophilia A/B treatment for non-inhibitor patients.

SystImmune and industry giant Bristol Myers Squibb have announced a partnership and licensing agreement focused on BL-B01D1, SystImmune's cutting-edge EGFRxHER3 bispecific antibody-drug conjugate.